PRECISE - A health economic approach to evaluate uncertain evidence in personalised medicine

PRECISE is a health economic project in the field of personalised medicine that is funded by NordForsk. PRECISE is an international collaboration between experienced researchers from Norway, Sweden and the UK. A collaboration with Nordic healthcare decisions makers provides a platform for improving national pharmacoeconomic guidelines.

About the Project

PRECISE will provide policy makers with insight into the trade-offs that need to be made when deciding on reimbursement for targeted interventions based on uncertain evidence. PRECISE will develop new methods which will draw on existing principles to deal with uncertainty and heterogeneity in the economic evaluation of personalised medicine. Multiple real case studies will be developed to demonstrate the value of the methods for informing reimbursement decisions for new health technologies.

Sub-projects

Workpage 1 (University of Oslo): Benefits and costs of early access to new health technologies when evidence is immature.

Workpage 2 (Linköping University): Right treatment to the right patient with the right evaluation methods and research portifolio.

Workpage 3 (University of Oslo): Recommendations for improving guidelines, such as national pharmaeconomic guidelines for reimbursement applications.

Financing

Nordforsk (Biotek2021) - Innovations in Personalised Medicine: Towards Implementation of Personalised Medicine in Health Care

Cooporation

Norwegian Medicines Agency

Norwegian Institute of Public Health

Department of Medical and Health Sciences, Linköping University

School of Health and Related Research (ScHARR), University of Sheffield

Centre for Health Economics, University of York

Population Health Sciences, University of Bristol

Start - Finish

May 2019 to May 2023

Published Mar. 10, 2020 8:06 AM - Last modified Mar. 10, 2020 8:16 AM